GCL
IBER.U

Glazer Capital LLC’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Glazer Capital LLC’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$10K – 519
2022
Q4 		$10K Hold
1,000
– – ﹤0.01% 471
2022
Q3 		$10K Hold
1,000
– – ﹤0.01% 636
2022
Q2 		$10K Hold
1,000
– – ﹤0.01% 648
2022
Q1 		$10K Buy
+1,000
New +$9.96K ﹤0.01% 514
2021
Q4 		– Sell
-211,064
Closed -$2.11M – 1001
2021
Q3 		$2.11M Sell
211,064
-14,296
-6% -$143K 0.04% 394
2021
Q2 		$2.27M Sell
225,360
-125,988
-36% -$1.26M 0.04% 420
2021
Q1 		$3.46M Buy
+351,348
New +$3.51M 0.05% 389

Glazer Capital LLC's IBER.U Position: Q1 2023 in Review

Glazer Capital LLC sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 1,000 shares — an estimated $10K sold.

Glazer Capital LLC first reported a position in IBER.U in Q1 2021 and held it in 7 quarters. The position peaked at $3.46M in Q1 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Glazer Capital LLC reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • Glazer Capital LLC sold 1,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $10K.
  • Glazer Capital LLC first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 7 quarters.
  • Glazer Capital LLC's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $3.46M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Glazer Capital LLC's 13F filing for Q1 2023, filed 15 May 2023.